Galectin Therapeutics (GALT) Change in Receivables (2011)
Galectin Therapeutics' quarterly Change in Receivables came in at -$234000.0 in Q1 2011.
Galectin Therapeutics has reported Change in Receivables for 1 years, with the latest figure at -$234000.0 in Q1 2011.
- For the quarter ending Q1 2011, Change in Receivables changed N/A year-over-year to -$234000.0; the trailing twelve-month figure through Dec 2011 stood at -$234000.0 (changed N/A YoY), and the FY2011 full-year result was -$234000.0, down 200.0% from the prior year.
- Change in Receivables for Q1 2011 stood at -$234000.0.
- The five-year high for Change in Receivables was -$234000.0 in Q1 2011, with the low at -$234000.0 in Q1 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2011 | -234,000.00 |
| Mar 31, 2011 | -234,000.00 |